Ticker Symbol: GNCA
Genocea Biosciences Inc
$1.63 - 20-12-2024 4 p.m. ET
Exchange: OTC MARKETS
Country:
US
Currency:
USD
Asset
Type: Common Stock
CIK:0001457612
Company Profile
Genocea's mission is to conquer cancer by developing personalized cancer immunotherapies in multiple tumor types. Our unique ATLAS™ platform comprehensively profiles each patient's T cell responses to potential targets, or antigens, on the tumor. ATLAS enables us to optimize the neoantigens for inclusion in our immunotherapies and exclude inhibitory antigens, Inhibigens™, that can exert an immunosuppressive effect. We are advancing two ATLAS-enabled programs: GEN-009, our neoantigen vaccine and GEN-011, our neoantigen-specific cell therapy using T cells derived from peripheral blood.
Sector: Manufacturing
Industry: Biological Product (except Diagnostic) Manufacturing
Standard Industrial Classification Code (SIC code): 2836
Address: 100 Acorn Park Dr
Website: www.genocea.com
CEO: William Clark
Tags:
- Health Technology
- Biotechnology
- Manufacturing
- Biological Product (except Diagnostic) Manufacturing
Pricing
Last Updated: December 31, 1969 07:00 PM EST
Previous Close: -
Change:
-
(
0.00%)
Days Range: $0.05 - $0.05
Beta: -
52wk. High: -
52wk. Low: -
Ytd. Change 0.00%
50 Day Moving Average: -
200 Day Moving Average: -
Shares Outstanding: 58783503
Valuation
Market Cap: 299.8M
PE Ratio: -
EPS (TTM): 0
Dividends
Dividend Per Share (TTM): -
Dividend Yield (TTM): 0.00%
Ex-Dividend Date: N/A